M&A

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

News

Firefly in a jar illustration on black background

J&J lights up $1bn offer for pan-KRAS developer Firefly

Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.

News

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.

News

Lilly gets back in infectious disease, via three M&A deals

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8bn.

News

GBL joins CVC in €10.7bn takeover bid for Recordati

A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.

R&D

Why UCB bet a billion dollars on cell therapy for epilepsy

UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

J&J lights up $1bn offer for pan-KRAS developer Firefly

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Lilly gets back in infectious disease, via three M&A deals

GBL joins CVC in €10.7bn takeover bid for Recordati

Why UCB bet a billion dollars on cell therapy for epilepsy

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks